ROCKVILLE, MD and SHENZHEN, CHINA, November 2, 2023—HighTide Therapeutics, Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for metabolic and digestive diseases
November 02, 2023
Learn More
HighTide Therapeutics, Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic and digestive diseases, today announces that the company’s founder and CEO,
October 25, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, October 20, 2023— HighTide Therapeutics, Inc. (HighTide), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic
October 20, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, October 11, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic and digestive diseases
October 12, 2023
Learn More
HighTide Therapeutics, Inc. (“HighTide”) was invited to present at the Office for Attracting Strategic Enterprises (OASES) launching ceremony hosted by the Hong Kong government. HighTide, a company focused on the discovery and development o
October 05, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, October 3rd, 2023— HighTide Therapeutics, Inc. (“HighTide”) announces that the primary findings from the Phase 2 clinical trial of berberine ursodeoxycholate (HTD1801)
October 03, 2023
Learn More
© 2023 HighTide Therapeutics, Inc.